Related Experiment Video
Updated: Sep 6, 2025

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
Published on: February 2, 2021
Risk of polymyxin B-induced acute kidney injury with a non adjusted dose versus adjusted dose based on renal function
Guanhao Zheng1,2, Jiaqi Cai3, Shenghui Zhou4
1Department of Pharmacy, Ruijin Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, 200000, China.
Abstract:
Aim: To observe the difference in the risk of polymyxin B (PMB)-induced acute kidney injury (AKI) with or without dose adjustment based on the patients renal function. Materials & methods: This retrospective cohort analysis was carried out in 115 patients treated with PMB from November 2018 to October 2019. Results: No significant difference in the incidence of AKI as well as secondary outcomes was observed between these two groups (47.5 vs 37.14%; p = 0.304). Conclusion: Dosing adjustment based on renal function does not significantly lower the risk of PMB-induced AKI. A non adjusted dosing strategy for PMB is recommended in patients exhibiting various levels of renal impairment.
Insights
Dose adjustment of polymyxin B (PMB) based on kidney function did not significantly reduce acute kidney injury (AKI) risk. A non-adjusted dosing strategy is recommended for patients with varying renal impairment.
Area of Science:
- Pharmacology
- Nephrology
- Infectious Diseases
Background:
- Polymyxin B (PMB) is a critical antibiotic for treating multidrug-resistant Gram-negative infections.
- Acute kidney injury (AKI) is a significant adverse effect associated with PMB treatment.
- Optimal dosing strategies for PMB in patients with renal impairment are still debated.
Purpose of the Study:
- To compare the incidence of PMB-induced AKI between patients receiving PMB with dose adjustment versus those receiving standard dosing.
- To evaluate the impact of renal function-based PMB dose adjustment on secondary clinical outcomes.
Main Methods:
- Retrospective cohort study involving 115 patients treated with PMB from November 2018 to October 2019.
- Patients were divided into two groups: those with PMB dose adjustment based on renal function and those without.
- Incidence of AKI and secondary outcomes were compared between the groups.
Main Results:
- No statistically significant difference in AKI incidence was observed between the dose-adjusted group (47.5%) and the non-adjusted group (37.14%; p = 0.304).
- Secondary outcomes also showed no significant differences between the two treatment strategies.
- The study did not find evidence supporting the benefit of PMB dose adjustment for reducing AKI risk.
Conclusions:
- Renal function-based dose adjustment of polymyxin B does not significantly reduce the risk of acute kidney injury.
- A non-adjusted dosing strategy for PMB may be appropriate for patients with varying degrees of renal impairment.
- Further prospective studies are warranted to confirm these findings and optimize PMB therapy.
Related Concept Videos
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care
Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Acute Kidney Injury I: Introduction
Acute Kidney Injury II: Pathophysiology

